VivoSeq
Other

Left Ventricular Dysfunction

0

Pipeline Programs↗

2

Active Trials↗

2

Companies Involved↗

Left Ventricular Dysfunction is an early-stage landscape with 0 programs across 2 companies. The most active players are Berlin-Chemie Menarini, AstraZeneca.

Intelligence

Pipeline Metrics

Competitive Density

10/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

B

Berlin-Chemie Menarini

0 programs

PreclinicalAstraZeneca logo

AstraZeneca

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

10

clinical trials

Completed6 · 60%
Unknown status2 · 20%
Recruiting2 · 20%

Clinical Trials

Trial Activity

10 trials

Safety of Continuing HER-2 Directed Therapy in Overt Left Ventricular Dysfunction
Recruiting·PPopulation Health Research Institute·Phase 2·NCT04680442·130 enrolled
Human Embryonic Stem Cell-Derived Cardiomyocyte Therapy for Chronic Ischemic Left Ventricular Dysfunction
Recruiting·—·Phase 1·NCT05068674·18 enrolled
Effects of Rosiglitazone on Plasma BNP Levels and Left Ventricular Dysfunction
Completed·—·Phase 4·NCT00300911·45 enrolled
Safety of Continuing CHemotherapy in Overt Left Ventricular Dysfunction Using Antibodies to HER-2
Completed·PPopulation Health Research Institute·Phase 1·NCT02907021·20 enrolled
Effects of Nebivolol on Subclinical Left Ventricular dySfunction: A Comparative Study Against Metoprolol
Completed·BBerlin-Chemie Menarini·Phase 3·NCT00942487·60 enrolled
Studies of Left Ventricular Dysfunction (SOLVD)
Completed·National Heart, Lung, and Blood Institute (NHLBI)·Phase 3·NCT00000516
Investigate the Effect of AZD1305 on Patients With Left Ventricular Dysfunction
Completed·AstraZeneca logoAstraZeneca·Phase 2·NCT00748982·16 enrolled
Prevention of Left Ventricular Dysfunction During Chemotherapy
Completed·HHospital Clinic of Barcelona·Phase 3·NCT01110824·90 enrolled
Sex Differences in Myocardial Steatosis Induced Left Ventricular Dysfunction
Unknown status·TThe University of Texas at Arlington·Phase 4·NCT04671966·100 enrolled
UC-MSC Transplantation for Left Ventricular Dysfunction After AMI
Unknown status·SShanghai Life Science & Technology·Phase 1·NCT03902067·40 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)